In Brief: BRCA1 and BRCA2

Journal of Pathology

Volumn 230, Issue 4, 2013, Pages 347-349

  Foulkes, William D ^a   Shuen, Andrew Y ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

breast cancer; cisplatinum; DNA repair; ovarian cancer; PARP; pathology; targeted therapy; triple negative

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ARTICLE; BREAST CANCER; BREAST DEVELOPMENT; CANCER LOCALIZATION; CANCER RISK; CANCER SUSCEPTIBILITY; DNA ADDUCT; DNA END JOINING REPAIR; DNA REPAIR; DNA SEQUENCE; DOUBLE STRANDED DNA BREAK; GENE SEQUENCE; GENETIC SCREENING; HAPLOINSUFFICIENCY; HOMOLOGOUS RECOMBINATION; HUMAN; MISSENSE MUTATION; MUTATION; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SINGLE STRANDED DNA BREAK;

BREAST CANCER; CISPLATINUM; DNA REPAIR; OVARIAN CANCER; PARP; PATHOLOGY; TARGETED THERAPY; TRIPLE NEGATIVE;

ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; DNA BREAKS, DOUBLE-STRANDED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; MUTATION; OVARIAN NEOPLASMS; PHENOTYPE; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880115555     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4205     Document Type: Article

References (5)

1. Narod SA, Foulkes WD,. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004; 4: 665-676.
2. Silver DP, Livingston DM,. Mechanisms of BRCA1 tumor suppression. Cancer Discov 2012; 2: 679-684.
3. Barber LJ, Sandhu S, Chen L, et al,. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol 2013; 229: 422-429.
4. Drost RM, Jonkers J,. Preclinical mouse models for BRCA1-associated breast cancer. Br J Cancer 2009; 101: 1651-1657.
5. http://ccge.medschl.cam.ac.uk/boadicea/